Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

BACKGROUND: Programmed death receptor-1 (PD-1) blockade shows little benefit in patients with microsatellite-stable colorectal cancer (MSS-CRC). Fruquintinib is a China-made anti-angiogenic drug which is approved for the third line therapy in mCRC. This study investigates the effect of the combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingli, Cheng, Xiaojiao, Zhou, Cong, Tang, Yao, Li, Fuli, Zhang, Baiwen, Huang, Tinglei, Wang, Jianzheng, Tu, Shuiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968679/
https://www.ncbi.nlm.nih.gov/pubmed/35371995
http://dx.doi.org/10.3389/fonc.2022.841977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968679/
https://www.ncbi.nlm.nih.gov/pubmed/35371995
http://dx.doi.org/10.3389/fonc.2022.841977

Ejemplares similares